Purchase this article with an account.
K. Hirooka, T. Baba, T. Fujimura, F. Shiraga; Prevention of Visual Field Defect Progression With Angiotensin–Converting Enzyme Inhibitor in Eyes With Normal–Tension Glaucoma . Invest. Ophthalmol. Vis. Sci. 2006;47(13):1565.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the effect of angiotensin–converting enzyme (ACE) inhibitor on visual field changes in normal–tension glaucoma (NTG).
We retrospectively reviewed a total of 38 patients with NTG. NTG patients with hypertension were divided into two groups, those receiving ACE inhibitor (n = 12) and those receiving other antihypertensive drug (n = 13). Control subjects (n = 13) had no previous history of hypertension. HfaFiles 5, an analytical program for the Humphrey Field Analyzer, with which we can perform a linear regression analysis of mean deviation (MD) of visual fields obtained during the follow–up period, was used to calculate the slope of the MD change per year.
In the ACE inhibitor–treated group, the mean MD change per year was 0.48±0.19 dB, while it was –0.38±0.23 dB in control subjects and –0.50±0.39 dB in the other antihypertensive drug–treated group (ACE inhibitor–treated group vs. control subjects, P =0.04; ACE inhibitor–treated group vs. other antihypertensive drug–treated group, P =0.02).
ACE inhibitor seems to have a favorable effect on the visual field in patients with NTG. However, a randomized controlled study is needed to prove the effect of ACE inhibitors in eyes with NTG.
This PDF is available to Subscribers Only